Literature DB >> 20444451

Association of Lp-PLA(2) activity with allele-specific Lp(a) levels in a bi-ethnic population.

Byambaa Enkhmaa1, Erdembileg Anuurad, Wei Zhang, Thomas A Pearson, Lars Berglund.   

Abstract

OBJECTIVES: Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and lipoprotein(a) [Lp(a)] have been implicated as cardiovascular disease risk factors, and are differentially regulated across ethnicity. We investigated the association between Lp-PLA(2) activity and allele-specific apolipoprotein(a) [apo(a)] levels in a bi-ethnic population.
METHODS: Lp-PLA(2) activity, Lp(a) and allele-specific apo(a) levels were determined in 224 African Americans and 336 Caucasians.
RESULTS: Lp-PLA(2) activity level was higher among Caucasians compared to African Americans (173 + or - 41 nmol/min/ml vs. 141 + or - 39 nmol/min/ml, P<0.001), and positively associated with Lp(a), total and LDL cholesterol, triglyceride, apolipoprotein B-100, and negatively with HDL cholesterol levels in both ethnic groups. The association between Lp-PLA(2) activity and Lp(a) was stronger among African Americans compared to Caucasians (R=0.238, beta(1)=3.48, vs. R=0.111, beta(1)=1.93, respectively). The Lp-PLA(2) activity level was significantly associated with allele-specific apo(a) levels for smaller (<26 K4 repeats) apo(a) sizes in both ethnic groups (P=0.015 for African Americans, P=0.038 for Caucasians). In contrast, for larger (>26 K4 repeats) apo(a) sizes, high Lp-PLA(2) activity levels were associated with higher allele-specific apo(a) levels in African Americans (P=0.009), but not in Caucasians.
CONCLUSION: The association between Lp-PLA(2) activity and allele-specific apo(a) levels differs across African American-Caucasian ethnicity. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20444451      PMCID: PMC2914160          DOI: 10.1016/j.atherosclerosis.2010.03.021

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  30 in total

1.  Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans.

Authors:  S M Marcovina; J J Albers; E Wijsman; Z Zhang; N H Chapman; H Kennedy
Journal:  J Lipid Res       Date:  1996-12       Impact factor: 5.922

2.  PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme.

Authors:  A D Tselepis; C Dentan; S A Karabina; M J Chapman; E Ninio
Journal:  Arterioscler Thromb Vasc Biol       Date:  1995-10       Impact factor: 8.311

3.  Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol.

Authors:  G R Warnick; J Benderson; J J Albers
Journal:  Clin Chem       Date:  1982-06       Impact factor: 8.327

4.  A mutation in plasma platelet-activating factor acetylhydrolase (Val279-->Phe) is a genetic risk factor for stroke.

Authors:  M Hiramoto; H Yoshida; T Imaizumi; N Yoshimizu; K Satoh
Journal:  Stroke       Date:  1997-12       Impact factor: 7.914

5.  Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein.

Authors:  D M Stafforini; L W Tjoelker; S P McCormick; D Vaitkus; T M McIntyre; P W Gray; S G Young; S M Prescott
Journal:  J Biol Chem       Date:  1999-03-12       Impact factor: 5.157

6.  Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations.

Authors:  E Boerwinkle; C C Leffert; J Lin; C Lackner; G Chiesa; H H Hobbs
Journal:  J Clin Invest       Date:  1992-07       Impact factor: 14.808

7.  Molecular definition of the extreme size polymorphism in apolipoprotein(a).

Authors:  C Lackner; J C Cohen; H H Hobbs
Journal:  Hum Mol Genet       Date:  1993-07       Impact factor: 6.150

8.  PAF-acetylhydrolase activity of Lp(a) before and during Cu(2+)-induced oxidative modification in vitro.

Authors:  S A Karabina; M C Elisaf; J Goudevenos; K C Siamopoulos; D Sideris; A D Tselepis
Journal:  Atherosclerosis       Date:  1996-08-23       Impact factor: 5.162

9.  Enhanced association of platelet-activating factor acetylhydrolase with lipoprotein (a) in comparison with low density lipoprotein.

Authors:  C Blencowe; A Hermetter; G M Kostner; H P Deigner
Journal:  J Biol Chem       Date:  1995-12-29       Impact factor: 5.157

10.  Apolipoprotein(a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: The Physicians' Health Study.

Authors:  Nader Rifai; Jing Ma; Frank M Sacks; Paul M Ridker; Wendy Jade L Hernandez; Meir J Stampfer; Santica M Marcovina
Journal:  Clin Chem       Date:  2004-05-20       Impact factor: 8.327

View more
  12 in total

1.  Differential associations of serum amyloid A and pentraxin-3 with allele-specific lipoprotein(a) levels in African Americans and Caucasians.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Zeynep Ozturk; Wei Zhang; Thomas A Pearson; Lars Berglund
Journal:  Transl Res       Date:  2011-02-05       Impact factor: 7.012

2.  Significant associations between lipoprotein(a) and corrected apolipoprotein B-100 levels in African-Americans.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Wei Zhang; Lars Berglund
Journal:  Atherosclerosis       Date:  2014-05-10       Impact factor: 5.162

Review 3.  Lipoprotein(a): genotype-phenotype relationship and impact on atherogenic risk.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Wei Zhang; Tina Tran; Lars Berglund
Journal:  Metab Syndr Relat Disord       Date:  2011-07-12       Impact factor: 1.894

4.  Lipoprotein(a) and HIV: Allele-Specific Apolipoprotein(a) Levels Predict Carotid Intima-Media Thickness in HIV-Infected Young Women in the Women's Interagency HIV Study.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Wei Zhang; Chin-Shang Li; Robert Kaplan; Jason Lazar; Dan Merenstein; Roksana Karim; Brad Aouizerat; Mardge Cohen; Kenneth Butler; Savita Pahwa; Igho Ofotokun; Adaora A Adimora; Elizabeth Golub; Lars Berglund
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-03-23       Impact factor: 8.311

5.  Apo E4 and lipoprotein-associated phospholipase A2 synergistically increase cardiovascular risk.

Authors:  Zeynep Gungor; Erdembileg Anuurad; Byambaa Enkhmaa; Wei Zhang; Kyoungmi Kim; Lars Berglund
Journal:  Atherosclerosis       Date:  2012-05-08       Impact factor: 5.162

6.  The roles of apo(a) size, phenotype, and dominance pattern in PCSK9-inhibition-induced reduction in Lp(a) with alirocumab.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Wei Zhang; Kun Yue; Ching-Shang Li; Lars Berglund
Journal:  J Lipid Res       Date:  2017-08-10       Impact factor: 5.922

7.  HIV disease activity as a modulator of lipoprotein(a) and allele-specific apolipoprotein(a) levels.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Wei Zhang; Adnan Abbuthalha; Xiao-Dong Li; William Dotterweich; Richard B Pollard; David M Asmuth; Lars Berglund
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-11-29       Impact factor: 8.311

Review 8.  Lipoprotein (a): impact by ethnicity and environmental and medical conditions.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Lars Berglund
Journal:  J Lipid Res       Date:  2015-12-04       Impact factor: 5.922

9.  Effect of antiretroviral therapy on allele-associated Lp(a) level in women with HIV in the Women's Interagency HIV Study.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Wei Zhang; Chin-Shang Li; Robert Kaplan; Jason Lazar; Dan Merenstein; Roksana Karim; Brad Aouizerat; Mardge Cohen; Kenneth Butler; Savita Pahwa; Igho Ofotokun; Adaora A Adimora; Elizabeth Golub; Lars Berglund
Journal:  J Lipid Res       Date:  2018-07-16       Impact factor: 5.922

10.  Lipoprotein(a) and apolipoprotein(a) in polycystic ovary syndrome.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Wei Zhang; Adnan Abbuthalha; Parneet Kaur; Jasmeen Visla; Sidika Karakas; Lars Berglund
Journal:  Clin Endocrinol (Oxf)       Date:  2015-10-05       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.